O	0	5	PTHrP	PTHrP	NN	B-NP
O	6	12	drives	drive	VBZ	B-VP
B-Cancer	13	19	breast	breast	NN	B-NP
I-Cancer	20	25	tumor	tumor	NN	I-NP
O	26	36	initiation	initiation	NN	I-NP
O	36	37	,	,	,	O
O	38	49	progression	progression	NN	B-NP
O	49	50	,	,	,	O
O	51	54	and	and	CC	O
O	55	65	metastasis	metastasis	NN	B-NP
O	66	68	in	in	IN	B-PP
O	69	73	mice	mouse	NNS	B-NP
O	74	77	and	and	CC	O
O	78	80	is	be	VBZ	B-VP
O	81	82	a	a	DT	B-NP
O	83	92	potential	potential	JJ	I-NP
O	93	100	therapy	therapy	NN	I-NP
O	101	107	target	target	NN	I-NP
O	107	108	.	.	.	O

O	110	121	Parathyroid	Parathyroid	JJ	B-NP
O	122	129	hormone	hormone	NN	I-NP
O	129	130	-	-	HYPH	B-VP
O	130	137	related	relate	VBN	B-NP
O	138	145	protein	protein	NN	I-NP
O	146	147	(	(	(	O
O	147	152	PTHrP	PTHrP	NN	B-NP
O	152	153	)	)	)	O
O	154	156	is	be	VBZ	B-VP
O	157	158	a	a	DT	B-NP
O	159	167	secreted	secrete	VBN	I-NP
O	168	174	factor	factor	NN	I-NP
O	175	184	expressed	express	VBN	B-VP
O	185	187	in	in	IN	B-PP
O	188	194	almost	almost	RB	B-NP
O	195	198	all	all	DT	I-NP
O	199	205	normal	normal	JJ	I-NP
B-Tissue	206	211	fetal	fetal	JJ	I-NP
O	212	215	and	and	CC	I-NP
B-Tissue	216	221	adult	adult	JJ	I-NP
I-Tissue	222	229	tissues	tissue	NNS	I-NP
O	229	230	.	.	.	O

O	231	233	It	It	PRP	B-NP
O	234	236	is	be	VBZ	B-VP
O	237	245	involved	involve	VBN	I-VP
O	246	248	in	in	IN	B-PP
O	249	250	a	a	DT	B-NP
O	251	255	wide	wide	JJ	I-NP
O	256	261	range	range	NN	I-NP
O	262	264	of	of	IN	B-PP
O	265	278	developmental	developmental	JJ	B-NP
O	279	282	and	and	CC	I-NP
O	283	296	physiological	physiological	JJ	I-NP
O	297	306	processes	process	NNS	I-NP
O	306	307	,	,	,	O
O	308	317	including	include	VBG	B-PP
B-Organism_substance	318	323	serum	serum	NN	B-NP
O	324	331	calcium	calcium	NN	I-NP
O	332	342	regulation	regulation	NN	I-NP
O	342	343	.	.	.	O

O	344	349	PTHrP	PTHrP	NN	B-NP
O	350	352	is	be	VBZ	B-VP
O	353	357	also	also	RB	I-VP
O	358	368	associated	associate	VBN	I-VP
O	369	373	with	with	IN	B-PP
O	374	377	the	the	DT	B-NP
O	378	389	progression	progression	NN	I-NP
O	390	392	of	of	IN	B-PP
B-Cancer	393	401	skeletal	skeletal	JJ	B-NP
I-Cancer	402	412	metastases	metastasis	NNS	I-NP
O	412	413	,	,	,	O
O	414	417	and	and	CC	O
O	418	421	its	its	PRP$	B-NP
O	422	434	dysregulated	dysregulate	VBN	I-NP
O	435	445	expression	expression	NN	I-NP
O	446	448	in	in	IN	B-PP
O	449	457	advanced	advance	VBN	B-NP
B-Cancer	458	465	cancers	cancer	NNS	I-NP
O	466	472	causes	cause	VBZ	B-VP
O	473	483	malignancy	malignancy	NN	B-NP
O	483	484	-	-	HYPH	O
O	484	494	associated	associate	VBN	B-NP
O	495	508	hypercalcemia	hypercalcemia	NN	I-NP
O	508	509	.	.	.	O

O	510	518	Although	Although	IN	B-SBAR
O	519	524	PTHrP	PTHrP	NN	B-NP
O	525	527	is	be	VBZ	B-VP
O	528	538	frequently	frequently	RB	I-VP
O	539	548	expressed	express	VBN	I-VP
O	549	551	by	by	IN	B-PP
B-Cancer	552	558	breast	breast	NN	B-NP
I-Cancer	559	565	tumors	tumor	NNS	I-NP
O	566	569	and	and	CC	O
O	570	575	other	other	JJ	B-NP
B-Cancer	576	581	solid	solid	JJ	I-NP
I-Cancer	582	589	cancers	cancer	NNS	I-NP
O	589	590	,	,	,	O
O	591	594	its	its	PRP$	B-NP
O	595	602	effects	effect	NNS	I-NP
O	603	605	on	on	IN	B-PP
B-Cancer	606	611	tumor	tumor	NN	B-NP
O	612	623	progression	progression	NN	I-NP
O	624	627	are	be	VBP	B-VP
O	628	635	unclear	unclear	JJ	B-ADJP
O	635	636	.	.	.	O

O	637	641	Here	Here	RB	B-ADVP
O	641	642	,	,	,	O
O	643	645	we	we	PRP	B-NP
O	646	657	demonstrate	demonstrate	VBP	B-VP
O	658	660	in	in	IN	B-PP
O	661	665	mice	mouse	NNS	B-NP
O	666	677	pleiotropic	pleiotropic	JJ	B-NP
O	678	689	involvement	involvement	NN	I-NP
O	690	692	of	of	IN	B-PP
O	693	698	PTHrP	PTHrP	NN	B-NP
O	699	701	in	in	IN	B-PP
O	702	705	key	key	JJ	B-NP
O	706	711	steps	step	NNS	I-NP
O	712	714	of	of	IN	B-PP
B-Cancer	715	721	breast	breast	NN	B-NP
I-Cancer	722	728	cancer	cancer	NN	I-NP
O	729	730	-	-	HYPH	O
O	731	733	it	it	PRP	B-NP
O	734	744	influences	influence	VBZ	B-VP
O	745	748	the	the	DT	B-NP
O	749	759	initiation	initiation	NN	I-NP
O	760	763	and	and	CC	I-NP
O	764	775	progression	progression	NN	I-NP
O	776	778	of	of	IN	B-PP
B-Cancer	779	786	primary	primary	JJ	B-NP
I-Cancer	787	793	tumors	tumor	NNS	I-NP
O	794	797	and	and	CC	I-NP
B-Cancer	798	808	metastases	metastasis	NNS	I-NP
O	808	809	.	.	.	O

O	810	815	Pthrp	Pthrp	NN	B-NP
O	816	824	ablation	ablation	NN	I-NP
O	825	827	in	in	IN	B-PP
O	828	831	the	the	DT	B-NP
B-Tissue	832	839	mammary	mammary	JJ	I-NP
I-Tissue	840	850	epithelium	epithelium	NN	I-NP
O	851	853	of	of	IN	B-PP
O	854	857	the	the	DT	B-NP
O	858	862	PyMT	PyMT	NN	I-NP
O	862	863	-	-	HYPH	I-NP
O	863	867	MMTV	MMTV	NN	I-NP
B-Cancer	868	874	breast	breast	NN	I-NP
I-Cancer	875	881	cancer	cancer	NN	I-NP
O	882	887	mouse	mouse	NN	I-NP
O	888	893	model	model	NN	I-NP
O	894	900	caused	cause	VBD	B-VP
O	901	902	a	a	DT	B-NP
O	903	908	delay	delay	NN	I-NP
O	909	911	in	in	IN	B-PP
B-Cancer	912	919	primary	primary	JJ	B-NP
I-Cancer	920	925	tumor	tumor	NN	I-NP
O	926	936	initiation	initiation	NN	I-NP
O	936	937	,	,	,	O
O	938	947	inhibited	inhibit	VBD	B-VP
B-Cancer	948	953	tumor	tumor	NN	B-NP
O	954	965	progression	progression	NN	I-NP
O	965	966	,	,	,	O
O	967	970	and	and	CC	O
O	971	978	reduced	reduce	VBD	B-VP
O	979	989	metastasis	metastasis	NN	B-NP
O	990	992	to	to	TO	B-PP
B-Multi-tissue_structure	993	999	distal	distal	JJ	B-NP
I-Multi-tissue_structure	1000	1005	sites	site	NNS	I-NP
O	1005	1006	.	.	.	O

O	1007	1022	Mechanistically	Mechanistically	RB	B-ADVP
O	1022	1023	,	,	,	O
O	1024	1026	it	it	PRP	B-NP
O	1027	1034	reduced	reduce	VBD	B-VP
O	1035	1045	expression	expression	NN	B-NP
O	1046	1048	of	of	IN	B-PP
O	1049	1058	molecular	molecular	JJ	B-NP
O	1059	1066	markers	marker	NNS	I-NP
O	1067	1069	of	of	IN	B-PP
B-Cell	1070	1074	cell	cell	NN	B-NP
O	1075	1088	proliferation	proliferation	NN	I-NP
O	1089	1090	(	(	(	O
O	1090	1094	Ki67	Ki67	NN	B-NP
O	1094	1095	)	)	)	O
O	1096	1099	and	and	CC	O
O	1100	1112	angiogenesis	angiogenesis	NN	B-NP
O	1113	1114	(	(	(	O
O	1114	1120	factor	factor	NN	B-NP
O	1121	1125	VIII	VIII	CD	I-NP
O	1125	1126	)	)	)	O
O	1126	1127	,	,	,	O
O	1128	1141	antiapoptotic	antiapoptotic	JJ	B-NP
O	1142	1148	factor	factor	NN	I-NP
O	1149	1152	Bcl	Bcl	NN	I-NP
O	1152	1153	-	-	HYPH	O
O	1153	1154	2	2	CD	B-NP
O	1154	1155	,	,	,	O
B-Cell	1156	1160	cell	cell	NN	B-NP
O	1160	1161	-	-	HYPH	B-NP
O	1161	1166	cycle	cycle	NN	I-NP
O	1167	1178	progression	progression	NN	I-NP
O	1179	1188	regulator	regulator	NN	I-NP
O	1189	1195	cyclin	cyclin	NN	I-NP
O	1196	1198	D1	D1	NN	I-NP
O	1198	1199	,	,	,	O
O	1200	1203	and	and	CC	O
O	1204	1212	survival	survival	NN	B-NP
O	1213	1219	factor	factor	NN	I-NP
O	1220	1224	AKT1	AKT1	NN	I-NP
O	1224	1225	.	.	.	O

O	1226	1231	PTHrP	PTHrP	NN	B-NP
O	1232	1236	also	also	RB	B-ADVP
O	1237	1247	influenced	influence	VBD	B-VP
O	1248	1258	expression	expression	NN	B-NP
O	1259	1261	of	of	IN	B-PP
O	1262	1265	the	the	DT	B-NP
O	1266	1274	adhesion	adhesion	NN	I-NP
O	1275	1281	factor	factor	NN	I-NP
O	1282	1287	CXCR4	CXCR4	NN	I-NP
O	1287	1288	,	,	,	O
O	1289	1292	and	and	CC	O
O	1293	1305	coexpression	coexpression	NN	B-NP
O	1306	1308	of	of	IN	B-PP
O	1309	1314	PTHrP	PTHrP	NN	B-NP
O	1315	1318	and	and	CC	I-NP
O	1319	1324	CXCR4	CXCR4	NN	I-NP
O	1325	1328	was	be	VBD	B-VP
O	1329	1336	crucial	crucial	JJ	B-ADJP
O	1337	1340	for	for	IN	B-PP
O	1341	1351	metastatic	metastatic	JJ	B-NP
O	1352	1358	spread	spread	NN	I-NP
O	1358	1359	.	.	.	O

O	1360	1371	Importantly	Importantly	RB	B-ADVP
O	1371	1372	,	,	,	O
O	1373	1378	PTHrP	PTHrP	NN	B-NP
O	1378	1379	-	-	HYPH	O
O	1379	1387	specific	specific	JJ	B-NP
O	1388	1400	neutralizing	neutralize	VBG	I-NP
O	1401	1411	antibodies	antibody	NNS	I-NP
O	1412	1418	slowed	slow	VBD	B-VP
O	1419	1422	the	the	DT	B-NP
O	1423	1434	progression	progression	NN	I-NP
O	1435	1438	and	and	CC	I-NP
O	1439	1449	metastasis	metastasis	NN	I-NP
O	1450	1452	of	of	IN	B-PP
O	1453	1458	human	human	JJ	B-NP
B-Cancer	1459	1465	breast	breast	NN	I-NP
I-Cancer	1466	1472	cancer	cancer	NN	I-NP
I-Cancer	1473	1483	xenografts	xenograft	NNS	I-NP
O	1483	1484	.	.	.	O

O	1485	1488	Our	Our	PRP$	B-NP
O	1489	1493	data	datum	NNS	I-NP
O	1494	1502	identify	identify	VBP	B-VP
O	1503	1507	what	what	WP	B-NP
O	1508	1510	we	we	PRP	B-NP
O	1511	1518	believe	believe	VBP	B-VP
O	1519	1521	to	to	TO	I-VP
O	1522	1524	be	be	VB	I-VP
O	1525	1528	new	new	JJ	B-NP
O	1529	1538	functions	function	NNS	I-NP
O	1539	1542	for	for	IN	B-PP
O	1543	1548	PTHrP	PTHrP	NN	B-NP
O	1549	1551	in	in	IN	B-PP
O	1552	1559	several	several	JJ	B-NP
O	1560	1563	key	key	JJ	I-NP
O	1564	1569	steps	step	NNS	I-NP
O	1570	1572	of	of	IN	B-PP
B-Cancer	1573	1579	breast	breast	NN	B-NP
I-Cancer	1580	1586	cancer	cancer	NN	I-NP
O	1587	1590	and	and	CC	O
O	1591	1598	suggest	suggest	VBP	B-VP
O	1599	1603	that	that	IN	B-SBAR
O	1604	1609	PTHrP	PTHrP	NN	B-NP
O	1610	1613	may	may	MD	B-VP
O	1614	1624	constitute	constitute	VB	I-VP
O	1625	1626	a	a	DT	B-NP
O	1627	1632	novel	novel	JJ	I-NP
O	1633	1639	target	target	NN	I-NP
O	1640	1643	for	for	IN	B-PP
O	1644	1655	therapeutic	therapeutic	JJ	B-NP
O	1656	1668	intervention	intervention	NN	I-NP
O	1668	1669	.	.	.	O

